Currently, there are 1.13B common shares owned by the public and among those 1.13B shares have been available to trade.
The company’s stock has a 5-day price change of -5.07% and -9.74% over the past three months. TEVA shares are trading 57.95% year to date (YTD), with the 12-month market performance up to 88.24% higher. It has a 12-month low price of $8.64 and touched a high of $19.31 over the same period. TEVA has an average intraday trading volume of 6.52 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -7.30%, -7.10%, and 2.58% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Teva- Pharmaceutical Industries Ltd. ADR (NYSE: TEVA) shares accounts for 56.95% of the company’s 1.13B shares outstanding.
It has a market capitalization of $18.68B and a beta (3y monthly) value of 0.82. The earnings-per-share (ttm) stands at -$0.85. Price movements for the stock have been influenced by the stock’s volatility, which stands at 2.27% over the week and 2.69% over the month.
Analysts forecast that Teva- Pharmaceutical Industries Ltd. ADR (TEVA) will achieve an EPS of 0.69 for the current quarter, 0.55 for the next quarter and 2.78 for current fiscal year. The lowest estimate earnings-per-share for the quarter is 0.67 while analysts give the company a high EPS estimate of 0.67. Comparatively, EPS for the current quarter was 1.0 a year ago. Earnings per share for the fiscal year are expected to decrease by -3.50%, and 12.64% over the next financial year. EPS should shrink at an annualized rate of 0.24% over the next five years, compared to 26.63% over the past 5-year period.
Looking at the support for the TEVA, a number of firms have released research notes about the stock. Argus stated their Buy rating for the stock in a research note on July 10, 2024, with the firm’s price target at $20. JP Morgan coverage for the Teva- Pharmaceutical Industries Ltd. ADR (TEVA) stock in a research note released on March 08, 2024 offered a Neutral rating with a price target of $14. Piper Sandler was of a view on February 12, 2024 that the stock is Overweight, while Jefferies gave the stock Buy rating on January 23, 2024, issuing a price target of $10- $14. Piper Sandler on their part issued Neutral rating on January 03, 2024.
